Update, November 16, 2026
Rollins (ROL) closed at $39.29 on November 16, up 1.4% over the past five days while the S&P 500 fell 1.2% and the consumer‑discretionary XLY dropped 2.1%, keeping the stock’s outperformance intact.
The picture holds – the rally remains above the 35.7 $ swing‑zone support that defines a downside breakout, and the price is still under the 40 $ round resistance where sellers have historically emerged on rallies. The weekly downtrend persists, with the 40‑week average still above price, and the 50‑day SMA at $33.95 remains a key support target. A weekly close above the 52.14 $ swing‑zone would be required to shift the outlook.
Recent activity includes management’s upcoming presentations at investor conferences, noted by PR Newswire, and continued insider buying reported on November 3. No new earnings or macro events have altered the technical framework since the prior analysis.
Rollins Inc. (ROL) has bounced 24% in a month to $37.50, but the rally sits inside a weekly downtrend and has reached overbought, with the 14-day RSI at 72. The third-quarter report on October 22, 2026 missed on revenue and adjusted earnings as residential growth slowed, yet the stock recovered instead of breaking lower. The balance of evidence for the next two to six weeks leans negative, though conviction is low.
Why it matters
The quarter was a soft one. Revenue came in at $1.09 billion, up 6%, but organic growth slowed to 4.4%, and adjusted earnings of $0.34 per share missed the $0.35 consensus, with revenue short of the $1.11 billion expected. The weak spot was residential, where organic growth was only 2.3% amid pressure on digital customer acquisition, while commercial pest control grew 6.6% organically. Net income of $157.9 million was down 3% from a year earlier.
Much of this was already in the price. The stock is down about 31.5% over six months and 37.5% since the start of the year, and the miss did not produce a new low. Shares are up 10.3% over five days and 24.3% over a month. Nothing in the news explains today's 4.1% gain, and volume is about 7% below its 20-day average, so this is not a move driven by heavy buying.
The five-day numbers show the move belongs to the stock. SPY fell 2.1% over five days and the consumer discretionary ETF XLY rose 1.5%, while ROL gained 10.3%, which is 8.8 points more than its sector. Today XLY slipped 0.8% while ROL rose 4.1%. This is a rebound in one name, not a market or sector tide.
The argument over ROL is about the quality of growth. The cautious side is Canaccord, which cut its price target to $36 from $45 and kept a Hold rating, citing weak one-time pest control business. The firm's survey also found contract and subscription business steady, which is the constructive side: the recurring base is intact and commercial is growing. Valuation leaves little room for either camp. Across 17 analysts the consensus is hold, the mean price target is $37.24 and the shares trade 0.7% above it. Targets range from $26 to $46, so the stock sits mid-spread with no discount to the average view.
What the evidence says
The long-term thesis is weakened. The stock trades below its 40-week average and well under its 200-day average at $46.65, and it is 42.8% below its 52-week high of $65.60. Over 200 days it has lagged SPY by 23.2 points. That is the profile of a stock in a downtrend that is bouncing off a low, 26.3% above its 52-week low of $29.69. Slowing organic growth and a residential business under pressure give that downtrend a fundamental basis.
For the next two to six weeks the evidence leans negative, and conviction is low, 1 point of 4. Three things drive the reading. A rally inside the weekly downtrend has reached overbought. The stock has led SPY by 13.8% over 50 days, and it has led XLY by 8.2%, both against the direction of the larger trend. Rallies of this kind in a downtrend tend to run into sellers, and $40 is where they have shown up before.
The strongest case against this reading is the strength itself. The price is above its 10-week average and its 50-day average at $33.51. The stock has outrun the market and its sector, and it absorbed an earnings miss without making a new low. If that continues, the bounce could extend toward $40 and beyond. It does not tip the balance because the price remains under the 40-week average and the 200-day line, and the RSI is stretched. It is also the main reason conviction is not higher.
Levels that matter
With the weekly trend down, the structure holds below $40.00, a round number where sellers have appeared on rallies. The next resistance is $45.00, then the 200-day average at $46.65. The weekly downtrend would end only with a weekly close above $52.14, a former swing zone. That is well above the current price, so the trend has a long way to travel before it changes.
The downside breakout level is a daily close below $35.70, a swing zone, with $35.00 just beneath it. From there the first target is the 50-day average at $33.51, and the second is the 52-week low at $29.69. A breakout would be wrong above $40.32, which is $40 plus a quarter of the 14-day ATR of $1.28. Against that stop the reward-to-risk is 0.5 to 1 to the first target and 1.3 to 1 to the second. The math does not reach 3 to 1. It would need a much tighter stop, which means a bounce failing well below $40, or a target below the 52-week low.
What would change the picture
A weekly close above $52.14 would be the price signal that the downtrend has ended and buyers are back in control. The non-price fact that could produce it is a recovery in residential organic growth from the 2.3% reported in the third quarter, which would show digital customer acquisition working again. Growth like that would remove the main reason the stock has been de-rated.
What to watch
- Next earnings: the data lists October 21, 2026, which has passed, since the third-quarter report came out on October 22, so the next date is not yet set. The number that matters is residential organic growth against 2.3%.
- Sector: XLY has gained 6.5% over a month and moves ahead of company news. ROL has outrun it by 8.2 points over 50 days, so a turn lower in consumer discretionary would test that lead.
- Valuation: the price of $37.50 sits against a mean target of $37.24 and a consensus of hold. The stock offers no discount to analysts' average view, and the Canaccord target of $36 sits just below the price.